IQ-AI Limited's (LON:IQAI) David Smith says the focus of their work on StoneChecker's moved into the commercial phase following FDA clearance for the product in the US.
The software helps to identify the patients who would respond best to lithotripsy, which breaks up kidney stones using sound waves, or those where surgery might be more appropriate.
In the US alone, 600,000 people suffer from kidney stones each year and IQ-AI believes StoneChecker can save millions by eliminating unnecessary procedures.